0001127602-20-014704.txt : 20200429 0001127602-20-014704.hdr.sgml : 20200429 20200429190425 ACCESSION NUMBER: 0001127602-20-014704 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200427 FILED AS OF DATE: 20200429 DATE AS OF CHANGE: 20200429 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: REESE DAVID M CENTRAL INDEX KEY: 0001748434 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 20832365 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2020-04-27 0000318154 AMGEN INC AMGN 0001748434 REESE DAVID M ONE AMGEN CENTER DRIVE THOUSAND OAKS 1 EVP, Research and Development Common Stock 2020-04-27 4 F 0 168 236.28 D 39170 D These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 3,297 RSUs which vest in installments of 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; and 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. These shares include 1,138 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Andrea A. Robinson, Attorney-in-Fact for Dr. Reese 2020-04-29